3SOF

Profile :

PDL BioPharma Inc.
34801 Campus Drive
Fremont, CA 94555
United States - Map
Phone: 510-574-1400
Fax: 510-574-1500
Web Site: http://www.pdl.com

DETAILS  
Index Membership: S&P 400 MidCap
S&P 1500 Super Comp
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 977


BUSINESS SUMMARY  
PDL BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for life-threatening illness. The company markets three biopharmaceutical products: Cardene IV to reduce high blood pressure during or after surgery; Retavase for the improvement of ventricular function following acute myocardial infarction (AMI), the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI; and IV Busulfex, a chemotherapeutic agent that provides anti-tumor effect to eradicate residual malignancy, ablation of the bone marrow, and immunosuppression to prevent graft rejection. The company also has six product candidates in Phase 2 or Phase 3 clinical development, which include Terlipressin to treat type 1 hepatorenal syndrome; Nuvion for the treatment of Intravenous steroid-refractory ulcerative colitis; Ularitide to treat cute decompensated heart failures; Daclizumab for the treatment of asthma and related respiratory diseases, multiple sclerosis, and to prevent acute kidney transplant rejection; M200 for the treatment of solid tumors; and HuZAF to treat rheumatoid arthritis. PDL BioPharma sells its products through hospital-focused sales force primarily in the United States, Canada, Europe, and Asia. It has collaboration arrangements with Biogen Idec, Inc. The company, formerly known as Protein Design Labs, Inc., was founded in 1986. It changed its name to PDL BioPharma, Inc. in January 2006. PDL BioPharma is headquartered in Fremont, California.

Business Overview

BRIEF: For the six months ended 30 June 2006, PDL BioPharma Inc.'s revenues increased 63% to $195.5M. Net loss decreased 62% to $33.6M. Revenues reflect increase in product sales of Cardene IV & IV Busulfex, rise in royalty income and higher license, collaboration & other income due to income recognition from Biogen Idec & Roche collaborations. Net loss reflects the absence of $79.4M of acquired in-process research and development expense. http://www.pdl.com/

Oversold...oversold...oversold !

Recent CandleStick Analysis
Very Bullish
Sept-22-2006 Bullish Engulfing

Support @ $17.15...16.51
Resistance @ $18.94...20.33...29.29

52wk Range: 16.39 - 33.30

Volume: 1,991,423
Avg Vol (3m): 1,424,790

Technicals
MACD is Bullish
Stochastic is Bullish
Percentage Gainer

Last Price Quote is:
-0.85%below 13-day EMA
-0.53%below 50-day EMA
RS Rating: 69 

Fundamentals
Key Data:
Market Cap (M): $2,223.57 
P/E Ratio: NA 
PEG Ratio: -6.9 
Next Earnings: 11/07/2006
Last Analyst Rating: Neutral

Update....
Drug stocks gain; Genentech jumps on earnings report
Genentech would have reported adjusted earnings per share of 61 cents for the quarter. A poll of analysts by Thomson First Call estimated the biotech giant would have earnings of 56 cents a share, on revenue of $2.55 billion
Shares of PDL BioPharma Inc. (PDLI : pdl biopharma inc com
21.24, +0.18, +0.9%) were also higher, up 2% at $21.06. The biotech group receives royalties on Genentech's leading oncology drugs Herceptin and Avastin.

Technicals
Last Price Quote is:
2.44%above 13-day MA
1.16%above 50-day MA
RS Rating: 59 

Fundamentals
Key Data:
Market Cap (M): $2,154.66 
P/E Ratio: NA 
PEG Ratio: -6.98276 
Next Earnings: 03/05/2007
Last Analyst Rating: Underperform

Today's closing chart.......


52wk Range: 16.39 - 27.98
Volume: 1,385,335
Avg Vol (3m): 2,800,690

Technicals
MACD - Bearish

Last Price Quote is:
-5.43%below 13-day MA
-2.54%below 50-day MA
RS Rating: 91 

Fundamentals
Key Data:
Market Cap (M): $2,889.44 
P/E Ratio: NA 
PEG Ratio: 2.54138 
Next Earnings: 08/09/2007
Last Analyst Rating: Mkt Perform

PDL to spinoff unit, pay special dividend
Biotech firm will spinoff its biotechnology products, paying $4.25 special dividend to shareholders.
April 10, 2008: 5:15 PM EDT

REDWOOD CITY, Calif. (AP) -- PDL BioPharma Inc. said Thursday it will spinoff its biotechnology assets into a separate company and pay shareholders a special $4.25 dividend.

The dividend is payable to shareholders of record on May 5.

PDL (PDLI) said it will capitalize the new company with $375 million in cash. The company said the initial infusion of money, along with potential milestone payments, royalties, and the sale of the company's cardiovascular products will fund the biotech spinoff for about three years.

After the spinoff, the company said it will continue to hold rights to royalty revenue on all future and current licensed products. It said it would distribute future revenue to stockholders and does not plan to make any acquisitions. PDL expects that revenue to range from $240 million to $260 million in 2008.

The revenue comes from a various products, including sales of Genentech's (DNA) cancer drug Avastin and Elan Pharmaceuticals multiple sclerosis drug Tysabri.

The separation should be completed by the end of this year. Additional details on the operations of the two separate companies that will result from the spin-off will be disclosed later, PDL said.

Shares of PDL BioPharma rose 46 cents to close at $11.71. They gained 29 cents in the aftermarket.

1-Month Price Change 41.9%

Bio momentum .......
In attempts to realize more value for shareholders, PDL Biopharma had been shopping its business around before finally pulling the plug on the effort last month. The news that the company didn't get an anxious buyer and would instead cut jobs to restructure the company sent the stock into a tailspin. But recent news that the biotech firm would spin off a portion of its business and pay a healthy dividend has investors excited again.

The new plan calls for shareholders to receive a $4.25-per-share dividend, funded by roughly $500 million in spoils the company raked in when it sold off pieces of its marketed drug portfolio. The company will then split into two publicly traded entities -- one holding the rights to its antibody humanization royalty assets, and the other containing the rest of its biotechnology operations, with the promise in a pipeline of drugs in development.

PDL plans to capitalize the new biotech company with $375 million in cash designed to sustain operations for about three years while it advances the development of drugs toward commercialization. Investors in general see lots of promise in the company, maintaining a four-star rating for most of the past six months. Optimism with the new dual-company structure has kept PDL Biopharma in the bull camp, too, with 480 out of the 509 investors who've rated the company believing that it will beat the S&P going forward.


52wk Range: 9.07 - 27.98
Volume: 3,416,420
Avg Vol (3m): 3,717,630

Technicals
Last Price Quote is:
15.59%above 13-day MA
10.18%above 50-day MA
RS Rating: 21 

Fundamentals
Key Data:
Market Cap (M): $1,610.88 
P/E Ratio: NA 
PEG Ratio: -1.97586 
Next Earnings: 05/07/2008
Last Analyst Rating: Neutral

Updated chart look.......

PDL Biopharma shares rise on 4Q results, outlook
PDL Biopharma shares jump on 4th-quarter results, outlook for 2009
Tuesday March 3, 2009, 1:28 pm EST


NEW YORK (AP) -- Shares of PDL Biopharma Inc. jumped Tuesday after the drug developer reported fourth-quarter results above analyst estimates.

Related Quotes
Symbol Price Change
DNA 82.13 +0.54

ELN 5.58 -0.31

FACT 6.46 -0.04

PDLI 6.74 +1.15

The stock soared $1, or 17.9 percent, to $6.59 in afternoon trading. Shares have traded between $5.55 and $16.11 over the last 52 weeks.

On Monday, PDL reported a fourth-quarter profit above Wall Street forecasts on higher royalty revenue from drugs it helped develop. Those include cancer treatments Avastin and Herceptin, macular degeneration treatment Lucentis, and Tysabri for multiple sclerosis and Crohn's disease. Avastin, Herceptin and Lucentis are sold by Genentech Inc., and Tysabri is sold by Elan Corp.

Incline Village, Nev.-based PDL said it expects between $185 million to $200 million in net income after taxes, and revenue of $310 million to $325 million.

The company also declared two semiannual dividends of 50 cents each.

JMP Securities analyst Charles C. Duncan reaffirmed a "Market Outperform" rating on the stock but cut his price target to $9 from $16, to account for the spin-off of the company's biotech business. PDL spun off Facet Biotech Corp. during the fourth quarter, but still owns royalty rights to current and future products.



52wk Range: 5.55 - 16.11
Volume: 7,515,824
Avg Vol (3m): 2,205,880
Market Cap: 805.47M
P/E (ttm): 50.30
EPS (ttm): 0.13
Div & Yield: N/A (N/A)


Technicals
Percentage Gainer

Last Price Quote is:
12.29%above 13-day MA
0.84%above 50-day MA
RS Rating: 28 

Fundamentals
Key Data:
Market Cap (M): $701.51 
P/E Ratio: 13.20 
PEG Ratio: 0.169231 
Next Earnings: 05/07/2009
Last Analyst Rating: Neutral

NEW YORK (AP) -- Shares of PDL BioPharma Inc.(PDLI) jumped after the company said it expects a revenue boost in the second quarter from royalties on a mix of drugs, including the blockbuster cancer treatment Avastin and respiratory virus drug Synagis.


52wk Range: 5.20 - 12.70
Volume: 1,706,876
Avg Vol (3m): 2,234,580
Market Cap: 887.65M
P/E (ttm): 7.36
EPS (ttm): 1.01
Div & Yield: 1.00 (14.00%)

Technicals
13-day EMA Cross Above 50-day MA

Last Price Quote is:
6.75%above 13-day MA
7.10%above 50-day MA
RS Rating: 32 

Fundamentals
Key Data:
Market Cap (M): $855.39 
P/E Ratio: 5.31 
PEG Ratio: 0.238462 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy

PDL BioPharma rises on better-than-seen outlook
PDL BioPharma shares rise on better-than-expected revenue outlook for royalties
On Monday June 8, 2009, 10:19 am EDT

NEW YORK (AP) -- Shares of PDL BioPharma Inc. jumped Monday after the company said it expects a revenue boost in the second quarter from royalties on a mix of drugs, including the blockbuster cancer treatment Avastin and respiratory virus drug Synagis.

The biotechnology stock gained 22 cents, or 3.1 percent, to reach $7.38 in morning trading. Shares have traded between $5.20 and $12.70 over the last 52 weeks.

The Incline Village, Nev.-based company expects revenue of about $125 million during the quarter, up 18 percent from $106 million a year prior. Analysts polled by Thomson Reuters expect revenue of $114.7 million, on average.

The company receives royalties from Genentech Inc. on the cancer treatment Avastin and macular degeneration treatment Lucentis. Genentech is now part of Swiss-based Roche. PDL also receives royalties from Ireland-based Elan on sales of the multiple sclerosis drug Tysabri. Elan's partner on that drug is Biogen Idec Inc.

PDL is scheduled to report its second-quarter results Aug. 6.

BMO Capital Markets analyst Jason Zhang reaffirmed a "Outperform" rating and a $8 price target, and attributed the higher-than-expected guidance to royalty revenue from the respiratory virus drug Synagis, which is made by Medimmune, part of AstraZeneca.

"Because of an ongoing license litigation, the company had previously not included royalty on Synagis sales in its forecast," Zhang said.

The latest outlook now includes about $18.7 million from Synagis royalties.

updated chart look...

A strong case for PDLI

5-Star Stocks Poised to Pop: PDL BioPharma
Brian D. Pacampara
December 16, 2010


Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company PDL BioPharma (Nasdaq: PDLI) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at PDL's business and see what CAPS investors are saying about the stock right now.


On CAPS, 96% of the 842 members who have rated PDL believe the stock will outperform the S&P 500 going forward. These bulls include feynmanshomeboy and Idigmoney.

Just two months ago, fynmanshomeboy summed up the "wind-down" scenario for our community: "Payouts taper off from 2014-2015. Even without sales growth, royalties pay out $8 over that time period. That's the worst, probable case if litigation doesn't go against them."

While PDL receives all of its revenues from licenses that are, indeed, set to expire in a few years, our community continues to see tons of potential in the business. Thanks to its ultra capital-light business model -- in which it collects royalties from the likes of Elan (NYSE: ELN), Biogen Idec (Nasdaq: BIIB), and Eli Lilly (NYSE: LLY) -- PDL's three-year average return on capital (43.9%) easily tops that of listed rivals Amgen (10.9%), Seattle Genetics (-36.8%), and XOMA (-50.5%). With management actively seeking new license agreements, PDL's upside seems attractive.

CAPS member Idigmoney expands on the bull case:

This is a numbers decision: high consistent ROE/ROI, very low PEG ratio, almost $200 million in free cash flow, manageable debt ratio at about 4 years of current earnings, three or more years of positive operating cash flow. I like the light, patent-oriented business model.

PDL facts

Headquarters (founded)
Incline Village, Nev. (1986)

Market Cap
$863.2 million

Industry
Biotechnology

Trailing-12-Month Revenue
$327.1 million

Management
CEO John McLaughlin (since 2008)

CFO Christine Larson (since 2008)

Return on Capital (average, past 3 years)
43.9%

Cash/Debt
$227.2 million / $453 million

Competitors
Amgen (Nasdaq: AMGN)

Seattle Genetics (Nasdaq: SGEN)

XOMA (Nasdaq: XOMA)


Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool

PDLI  U.S. Patent and Trademark Office Terminates Interference...  by PR Newswire  Dec 20 2010 7:00AM 

INCLINE VILLAGE, Nev., Dec. 20, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (PDLI) today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,089, (the '089 Patent) and certain pending claims of Adair et al., U.S. Application No. 08/846,658, (the '658 Application) in favor of the Company's '089 Patent. The PTO held that the involved claims in the '658 Application, are not patentable. UCB Pharma S.A. is the assignee of the '658 Application.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com .

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

Biotech - portfolio of patents which pay royalties. 7% short.
Patent Office Favors PDLI

Day's Range: 6.33 - 6.41
52wk Range: 4.97 - 7.30
Volume: 692,874
Avg Vol (3m): 2,002,020
Market Cap: 893.25M
P/E (ttm): 8.03
EPS (ttm): 0.80
Div & Yield: N/A (N/A


Technicals
Last Price Quote is:
2.99%above 13-day EMA
9.27%above 50-day EMA
RS Rating: 81 

Why We Added PDL Biopharma
Jim Van Meerten

I added PDL Biopharma (PDLI) to the Barchart Van Meerten Specualtive portfolio --Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

Recent price momentum has given the stock a 100% Barchart technical buy signal, with 16 new highs and an 11.80% price appreciation in the last 20 sessions the stock looks great. The Relative Strength Index is 74.94% and rising. The stock trades around 6.31, which is above its 50 day moving average of 5.66.

Wall Street analysts look for sales to increase by 12.50% next year with earnings per share increasing by 37.40% for the same period. The 5 year projected EPS annual growth rate of 26.00% has resulted in 2 buy and 5 hold recommendations for their clients.

The Fools on Motley Fool have the CAPS members voting 807 to 34 that the stock will beat the market with the more experienced All Stars voting 301 to 9. Fool notes that the last 6 articles in Wall Street periodicals have all been positive.

The stock was added because:

•100% Barchart technical buy signal
•16 new highs and up 11.80% in the last month
•Wall Street brokerages\project double digit increases in sales and earnings
•Positive investor sentiment

Disclosure: I am long PDLI.
He would enjoy hearing your comments at [email protected].

PDLI Meets EPS, Beats on Top Line

Zacks Equity Research, On Tuesday November 16, 2010, 10:45 am EST

PDL BioPharma Inc. (NasdaqGS: PDLI - News) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite the increase in revenue, due to higher selling and general expenses.

Quarterly Details

Third quarter revenue of $86.4 million was higher than the Zacks Consensus Estimate of $84 million and about 21% above the year-ago revenue. The top-line increase resulted from higher 2Q10 sales of Roche's (Other OTC: RHHBY.PK - News) Avastin, Herceptin, and Lucentis, and Biogen/Elan's (BIIB/ELN) Tysabri, on which PDL BioPharma received royalties in 3Q10. Revenue was, however, in line with the company's guidance of $86 million provided in September 2010.

Quarterly general and administrative expenses increased from $5.3 million in the year-earlier quarter to $11.1 million in the third quarter of 2010. Legal costs of $8.7 million associated with the MedImmune and Roche litigations perpetrated the rise in expenses.

The company has been making changes to its capital structure to provide better returns to its shareholders. The company no longer has any 2023 notes outstanding. In October, the company completed an exchange of $92 million of the 2012 notes in which the note-holders received $92 million in new 2.875% convertible senior notes due February 15, 2015. Besides, the company sold another $88 million of the new 2015 notes.

On October 1, 2010, the company paid a dividend of 50 cents to all shareholders of record as of September 15, 2010. PDL BioPharma said that it will provide revenue guidance for the fourth quarter in early December.

Roche Litigation

The company provided an update on the Genentech/Roche/Novartis (NYSE: NVS - News) EU patent disagreement. The company is reasserting the validity of the supplementary protection certificates (SPCs) granted to it by countries in Europe, which Roche has questioned. Roche is asserting that it does not owe PDL BioPharma royalties on sales of Avastin, Herceptin, Lucentis and Xolair manufactured and sold outside the US.

PDL has filed a complaint against Roche and Novartis in Nevada to enforce its rights against Roche under the 2003 settlement agreement. PDL believes that Roche has breached the agreement, which could lead to payment of liquidated and other damages of up to $1 billion by Roche, including a retroactive royalty of 3.75% on past US sales.

In November 2010, Roche filed a motion claiming that the complaint should be dismissed as the 2003 agreement relates only to PDL's US patents and Nevada does not have jurisdiction over Roche. PDL BioPharma is expected to respond to the motion in December 2010. Meanwhile, Novartis is also expected to respond to PDL's complaint in December 2010.

Roche had paid royalty on products sold and manufactured outside the US in August 2010.  The next payment is due in November 2010. PDL is, however, not sure if Roche will pay royalties on international sales, estimated to be about 30% of overall sales in November.

Our View

We currently have a Neutral recommendation on PDL BioPharma. We are encouraged by the company's strong revenue growth and its initiatives to change its capital structure. However, we prefer to remain on the sidelines until the Roche litigation resolves. Apart from that, the Queen patents, from which the company derives a significant portion of its revenue, are set to expire in 2013-14. 

PDL BioPharma Provides Fourth Quarter 2010 Revenue Guidance of $74 Million

INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced revenue guidance for the fourth quarter ending December 31, 2010 of approximately $74 million, as compared with actual results of $58.3 million for the fourth quarter of 2009, a 27 percent year-over-year increase.  The growth is primarily driven by increased third quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® for which PDL receives royalties in the fourth quarter of 2010.  The royalty payment received from Genentech included royalties generated on all worldwide sales.

Sales of Avastin, Herceptin and Lucentis are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States.  The net sales thresholds and the applicable royalty rates for product that is made or sold in the United States are outlined below:   

Royalty Rate
 
Net sales up to $1.5 billion
3.0%
 
Net sales between $1.5 billion and $2.5 billion
2.5%
 
Net sales between $2.5 billion and $4.0 billion
2.0%
 
Net sales exceeding $4.0 billion
1.0%
 
Reported sales for Avastin increased 8.7 percent in the third quarter of 2010 when compared to the same period in 2009. Roche recently reported that global sales of Avastin for advanced colorectal, breast, lung and kidney cancer, and for relapsed glioblastoma, rose 11 percent in the first nine months of 2010 driven by strong positive uptake of the product overall.  Roche also reported that slower U.S. sales, especially in the third quarter, reflected regulatory and reimbursement uncertainty regarding the metastatic breast cancer indication.  Contributing to increased Avastin royalties were sales of Avastin that was both manufactured and sold outside the United States.  Ex-U.S. manufactured and sold Avastin sales represented 26 percent of total Avastin sales; there were no sales of ex-U.S. manufactured and sold Avastin prior to the fourth quarter of 2009. 

Reported sales for Herceptin increased 10.2 percent in the third quarter of 2010 when compared to the same period in 2009.  Roche recently announced that global sales of Herceptin for HER2-positive breast cancer and advanced stomach cancer increased eight percent in the first nine months of 2010 driven by further penetration in the early and metastatic breast cancer settings, particularly in emerging markets.  Additionally, Roche reported that sales continue to benefit from uptake in advanced HER2-positive stomach cancer in Europe and other markets.  Also contributing to increased Herceptin royalties were sales of Herceptin that was both manufactured and sold outside the United States.  Ex-U.S. manufactured and sold Herceptin sales represented 40 percent of total Herceptin sales in the third quarter of 2010 as compared with 22 percent in the third quarter of 2009.

Reported sales for Lucentis increased 30.8 percent in the third quarter of 2010 when compared to the same period in 2009.  Lucentis is approved for the treatment of age-related macular degeneration in the United States and in Europe and received approval for the treatment of macular edema following retinal vein occlusion in June 2010 in the United States.  Roche and Novartis recently reported that sales grew by 29 percent and 30 percent for the first nine months of 2010 in the United States and internationally, respectively.

Reported sales for Tysabri increased 10.9 percent in the third quarter of 2010 when compared to the same period in 2009.  Biogen Idec recently announced that at the end of September 2010, approximately 55,100 patients were on therapy worldwide representing an increase of 19 percent over the approximately 46,200 patients who were on therapy at the end of September 2009.  Tysabri royalties are determined at a flat rate as a percent of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, expressed or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:


•The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;

•The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;

•The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;

•Changes in any of the other assumptions on which PDL's projected royalty revenues are based;

•The outcome of pending litigation or disputes;

•The change in foreign currency exchange rate; and

•The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.


Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

PDL Biopharma(PDLI) was a notable winner on Monday after legendary hedge fund manager Seth Klarman's Baupost group disclosed a new position in the company. The fund bought 5.6 million shares in the company, making it among the top ten holdings in the portfolio by market value.

Day's Range: 5.34 - 5.60
52wk Range: 4.81 - 7.30
Volume: 5,696,399
Avg Vol (3m): 2,376,990
Market Cap: 762.65M
P/E (ttm): 6.86
EPS (ttm): 0.80
Div & Yield: N/A (N/A)

Technicals
Gap Up

Last Price Quote is:
RS Rating: 30 

Yesterday's trading session produced a nice move north...
With some good volume

Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
10.37%above 13-day EMA
5.00%above 50-day EMA
RS Rating: 23